Application of liposomal technologies for delivery of platinum analogs in oncology

Demin Liu1, Chunbai He1, Andrew Z Wang2, Wenbin Lin1 1Department of Chemistry, University of Chicago, Chicago, IL, USA; 2Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chap...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu D, He C, Wang AZ, Lin W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/7420e408e9064e9fa18a5a41fd305009
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7420e408e9064e9fa18a5a41fd305009
record_format	dspace
spelling	oai:doaj.org-article:7420e408e9064e9fa18a5a41fd3050092021-12-02T05:39:40ZApplication of liposomal technologies for delivery of platinum analogs in oncology1176-91141178-2013https://doaj.org/article/7420e408e9064e9fa18a5a41fd3050092013-08-01T00:00:00Zhttp://www.dovepress.com/application-of-liposomal-technologies-for-delivery-of-platinum-analogs-a14150https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Demin Liu1, Chunbai He1, Andrew Z Wang2, Wenbin Lin1 1Department of Chemistry, University of Chicago, Chicago, IL, USA; 2Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA Abstract: Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research. Keywords: liposome, platinum analog, drug delivery, cancerLiu DHe CWang AZLin WDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 3309-3319 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Liu D He C Wang AZ Lin W Application of liposomal technologies for delivery of platinum analogs in oncology
description	Demin Liu1, Chunbai He1, Andrew Z Wang2, Wenbin Lin1 1Department of Chemistry, University of Chicago, Chicago, IL, USA; 2Laboratory of Nano- and Translational Medicine, Department of Radiation Oncology, and Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA Abstract: Platinum-based chemotherapy, such as cisplatin, oxaliplatin, and carboplatin, is one of the most widely utilized classes of cancer therapeutics. While highly effective, the clinical applications of platinum-based drugs are limited by their toxicity profiles as well as suboptimal pharmacokinetic properties. Therefore, one of the key research areas in oncology has been to develop novel platinum analog drugs and engineer new platinum drug formulations to improve the therapeutic ratio further. Such efforts have led to the development of platinum analogs including nedaplatin, heptaplatin, and lobaplatin. Moreover, reformulating platinum drugs using liposomes has resulted in the development of L-NDPP (Aroplatin™), SPI-77, Lipoplatin™, Lipoxal™, and LiPlaCis®. Liposomes possess several attractive biological activities, including biocompatibility, high drug loading, and improved pharmacokinetics, that are well suited for platinum drug delivery. In this review, we discuss the various platinum drugs and their delivery using liposome-based drug delivery vehicles. We compare and contrast the different liposome platforms as well as speculate on the future of platinum drug delivery research. Keywords: liposome, platinum analog, drug delivery, cancer
format	article
author	Liu D He C Wang AZ Lin W
author_facet	Liu D He C Wang AZ Lin W
author_sort	Liu D
title	Application of liposomal technologies for delivery of platinum analogs in oncology
title_short	Application of liposomal technologies for delivery of platinum analogs in oncology
title_full	Application of liposomal technologies for delivery of platinum analogs in oncology
title_fullStr	Application of liposomal technologies for delivery of platinum analogs in oncology
title_full_unstemmed	Application of liposomal technologies for delivery of platinum analogs in oncology
title_sort	application of liposomal technologies for delivery of platinum analogs in oncology
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/7420e408e9064e9fa18a5a41fd305009
work_keys_str_mv	AT liud applicationofliposomaltechnologiesfordeliveryofplatinumanalogsinoncology AT hec applicationofliposomaltechnologiesfordeliveryofplatinumanalogsinoncology AT wangaz applicationofliposomaltechnologiesfordeliveryofplatinumanalogsinoncology AT linw applicationofliposomaltechnologiesfordeliveryofplatinumanalogsinoncology
_version_	1718400303667085312

Application of liposomal technologies for delivery of platinum analogs in oncology

Ejemplares similares